Recently, we demonstrated the great efficacy of recombinant granulysin in two in vivo tumor development models in nude mice, mammary carcinoma MDA-MB-231 and multiple myeloma NCI-H929 [8]. The gene discussed is GNLY; the disease is neoplasm.